Two-year outcomes data on Transcatheter Aortic Valve Replacement (TAVR) in low-risk patients were recently presented at the American College of Cardiology 2020 Annual Scientific Session. PARTNER 3 demonstrated that TAVR with the Sapien 3 valve was as safe and effective as traditional open surgical replacement for low risk patients with aortic stenosis (AS). The primary outcome of the study—the risk of death, stroke or rehospitalization at two years—was comparable between the two groups.